OncLive TV

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

Susan Bal, MD, discusses the toxicity profile of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, according to findings from a phase 1 trial.

Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Nausheen Ahmed, MD, discusses findings from a real-world subgroup analysis of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Matthew Frank, MD, PhD, discusses preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.

Edward S. Kim, MD, MBA, discusses the investigation of LP-300 plus chemotherapy in the phase 2 HARMONIC trial in patients with advanced lung adenocarcinoma.

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches. 

Benjamin Miron, MD, discusses findings and clinical implications from a study investigating molecular alterations in patients with intraductal carcinoma of the prostate.